The Shift From 'Managing' Depression to Actually Beating It
A growing consensus among psychiatrists is pushing back against a long-standing status quo in depression care: that reducing symptoms is good enough. According to a recent clinical analysis published in Psychiatric Times, leading clinicians are now urging colleagues to aim for full remission — not just symptom reduction — when treating patients with treatment-resistant depression (TRD). The piece argues that settling for "less bad" outcomes fails patients who deserve a genuine return to function and quality of life.
This isn't a fringe position. It reflects a broader reckoning within psychiatry about how TRD has historically been undertreated, with providers cycling patients through medication adjustments that blunt the worst symptoms without ever resolving the underlying condition. The new framing demands more — and it has real implications for anyone navigating depression care in 2026.
What 'Treatment-Resistant' Actually Means — and Why It Matters
Treatment-resistant depression is typically defined as depression that has not responded adequately to at least two different antidepressant regimens given at appropriate doses and durations. By some estimates, roughly one-third of people with major depressive disorder fall into this category. That's a significant portion of patients who have been trying — and not succeeding — with conventional first-line treatments.
The Psychiatric Times analysis highlights that clinicians are now encouraged to take a more aggressive, individualized approach to these cases. This includes weighing not just clinical efficacy but also patient-reported priorities: What does remission look like for this specific person? What side effect burden are they willing to tolerate? What functional outcomes matter most to them?
This patient-centered framing is a meaningful shift. For years, depression treatment decisions were largely driven by standardized protocols. The emerging model asks providers to stay in active dialogue with patients about what "getting better" actually means — and to keep adjusting until that target is reached, not just until the worst days become less frequent.
The article also underscores that balancing efficacy with tolerability remains one of the central clinical challenges. Many patients with TRD have already experienced significant side effects from prior medication trials. Any new intervention must account for that history.
Where Ketamine Fits in the Remission-Focused Model
For patients exploring ketamine therapy, this clinical shift is directly relevant. Ketamine — and its FDA-approved derivative esketamine (Spravato) — has emerged as one of the most significant tools available for TRD precisely because it operates differently from traditional antidepressants. Rather than targeting the serotonin system, ketamine works on glutamate receptors, often producing rapid antidepressant effects within hours or days rather than weeks.
That speed matters enormously in a remission-focused framework. If the clinical goal is true recovery — not just stabilization — then interventions that can produce fast, meaningful symptom relief give providers and patients more room to work. Ketamine can serve as a reset, creating a window in which other therapeutic supports (psychotherapy, lifestyle interventions, medication optimization) can gain traction.
Online ketamine providers are increasingly positioned within this model. Telehealth platforms that offer ketamine treatment for TRD typically begin with thorough screening to confirm that a patient genuinely meets criteria for treatment-resistant or hard-to-treat depression. That intake process isn't just a formality — it's the clinical foundation that determines whether ketamine is appropriate and how the treatment plan should be structured.
What the new guidance reinforces is that ketamine shouldn't be viewed as a last resort taken in isolation. It's most effective when integrated into a broader plan with defined goals, ongoing provider communication, and clear benchmarks for what success looks like. Patients considering online ketamine treatment should look for providers who ask these kinds of questions upfront — not just whether you've tried other medications, but what you're hoping to achieve and how your progress will be tracked over time.
Key Takeaway for Patients
If you've been told your depression is "managed" but you still don't feel like yourself, that may no longer be an acceptable clinical outcome. The standard of care is moving toward full remission as the goal. When evaluating any ketamine provider — online or in-person — ask directly: What does your team consider a successful treatment outcome, and how will we know if we've reached it? Providers who can answer that question clearly are operating at the standard the field now expects.
What to Look for When Choosing an Online Ketamine Provider
The remission-focused approach described in the Psychiatric Times piece has practical implications for how patients should vet online ketamine providers. Here's what that guidance translates to in a telehealth context:
- Thorough intake screening: Legitimate providers will want to understand your full psychiatric history, prior medication trials, and current functional status — not just confirm you have a diagnosis. This is how they establish whether TRD criteria are met and whether ketamine is clinically appropriate.
- Goal-setting conversations: The best providers will ask what remission looks like for you specifically. Vague promises of "feeling better" aren't enough. Look for structured assessments and defined outcome measures.
- Follow-up care: Ketamine without follow-up is a red flag. Remission-focused care requires monitoring — tracking how you're responding, adjusting the protocol if needed, and coordinating with any other providers involved in your care.
- Integration with therapy: Many online ketamine providers now offer or recommend concurrent psychotherapy. This isn't just a value-add; it reflects the clinical evidence that ketamine's effects are more durable when paired with therapeutic support.
- Transparent out-of-pocket costs: Most online ketamine treatment remains outside insurance coverage, though esketamine may have different coverage pathways. Ask for full cost disclosure upfront so financial barriers don't interrupt a treatment course mid-stream.
The clinical conversation is evolving quickly, and patients with TRD have more evidence-backed options than ever before. The key is finding providers who are keeping pace with that evolution — and who hold themselves to the same remission-focused standard that leading psychiatrists are now demanding across the field.
Source: Psychiatric Times — Different Approaches for Management of Treatment-Resistant Depression
Share